Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | VNN1 | O95497 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzophenone SCHEMBL8025701 | 0.90 | ALDH1A1 (0.74) | KMT2AMEN1ALDH1A1ATMTDP1 | |
| Benzophenone SCHEMBL27487800 | 0.88 | KMT2A (0.82) | KMT2AMEN1ALDH1A1ATMTDP1 | |
| Benzoic Acid SCHEMBL3313836 | 0.86 | NAPRT (0.67) | KMT2AMEN1ALDH1A1SRD5A2APP | |
| Benzophenone SCHEMBL4019789 | 0.85 | KMT2A (0.86) | KMT2AMEN1ALDH1A1ATMTDP1 | |
| Benzoic Acid SCHEMBL28647367 | 0.84 | NAPRT (0.64) | KMT2AMEN1ALDH1A1SRD5A2APP | |
| Benzoic Acid SCHEMBL27833807 | 0.84 | NAPRT (0.64) | KMT2AMEN1ALDH1A1SRD5A2APP | |
| Benzoic Acid SCHEMBL27846116 | 0.84 | NAPRT (0.64) | KMT2AMEN1ALDH1A1SRD5A2APP | |
| SCHEMBL6454355 | 0.84 | ALDH1A1 (0.64) | KMT2AMEN1ALDH1A1ATMTDP1 | |
| SCHEMBL229650 | 0.83 | KMT2A (1.00) | KMT2AMEN1ALDH1A1ATMTDP1 | |
| Thiobenzoic Acid SCHEMBL15816821 | 0.82 | CA12 (0.70) | KMT2AMEN1ALDH1A1APPGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101242832-B | Fused pyrazole as p38 MAP kinase inhibitors | HOFFMANN LA ROCHE | 2011-08-10 | — | — | CN | disclosed |
| CN-101248077-B | P38 map kinase inhibitors and methods for using the same | HOFFMANN LA ROCHE | 2011-07-20 | — | — | CN | disclosed |
| US-7608603-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| CN-101248077-A | P38 MAP kinase inhibitors and methods for using the same | HOFFMANN LA ROCHE (CH) | 2008-08-20 | — | — | CN | disclosed |
| CN-101242832-A | Fused pyrazole as p38 MAP kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | CN | disclosed |
| EP-1919914-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| EP-1919470-A1 | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| CN-1926139-A | Fused pyrazole derivatives | HOFFMANN LA ROCHE (CH) | 2007-03-07 | — | — | CN | disclosed |
| US-20070049597-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| WO-2007023105-A1 | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023115-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| EP-1737865-A1 | FUSED DERIVATIVES OF PYRAZOLE | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-03 | — | — | EP | disclosed |
| EP-1720878-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-15 | — | — | US | disclosed |
| WO-2005085248-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005085249-A1 | FUSED DERIVATIVES OF PYRAZOLE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | MAP3K1, MAPK1, MAP3K8 | KMT2A 2973/4885MEN1 3629/4885ALDH1A1 2715/4885 |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | MAP3K1, MAP3K21, MAP3K2 | KMT2A 2066/4885MEN1 2700/4885ALDH1A1 2726/4885 |
| US-20070049597-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAPK9, MAPK3 | KMT2A 3245/4885MEN1 4248/4885ALDH1A1 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.